Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Malignant Melanoma

  Free Subscription


1 BMC Cancer
2 Br J Dermatol
1 Cancer Lett
1 Clin Cancer Res
2 J Am Acad Dermatol
3 J Surg Oncol
1 Melanoma Res
1 Oncogene
1 Oncol Rep
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Cancer

  1. TSAKMAKLIS A, Farowski F, Zenner R, Lesker TR, et al
    TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
    BMC Cancer. 2023;23:1160.
    PubMed         Abstract available

    Br J Dermatol

  2. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.

  3. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    PubMed         Abstract available

    Cancer Lett

  4. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    PubMed         Abstract available

    Clin Cancer Res

  5. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.
    Clin Cancer Res. 2023 Nov 30. doi: 10.1158/1078-0432.CCR-23-1964.
    PubMed         Abstract available

    J Am Acad Dermatol

  6. PAN CX, Liu M, Lau CB, Lau WC, et al
    Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors.
    J Am Acad Dermatol. 2023 Nov 29:S0190-9622(23)03239.

  7. HAWRYLUK EB, Moustafa D, Barry KK, Bahrani E, et al
    Risk Factors and Outcomes of Melanoma in Children and Adolescents: A Retrospective Multicenter Study.
    J Am Acad Dermatol. 2023 Nov 29:S0190-9622(23)03238.
    PubMed         Abstract available

    J Surg Oncol

    Adjuvant therapy for stage IIB + IIC melanoma.
    J Surg Oncol. 2023 Nov 30. doi: 10.1002/jso.27534.

  9. KAKISH H, Lal T, Thuener JE, Bordeaux JS, et al
    Is sentinel lymph node biopsy needed for lentigo maligna melanoma?
    J Surg Oncol. 2023 Nov 29. doi: 10.1002/jso.27543.
    PubMed         Abstract available

  10. GOYAL A, Fei-Zhang DJ, Pawlik TM, Bentrem DJ, et al
    Associations of social vulnerability with truncal and extremity melanomas in the United States.
    J Surg Oncol. 2023 Nov 27. doi: 10.1002/jso.27532.
    PubMed         Abstract available

    Melanoma Res

  11. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
    Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
    Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
    PubMed         Abstract available


  12. KURTENBACH S, Sanchez MI, Kuznetsoff J, Rodriguez DA, et al
    PRAME induces genomic instability in uveal melanoma.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02887.
    PubMed         Abstract available

    Oncol Rep

  13. CHEN XE, Chen P, Chen SS, Ma T, et al
    [Rectacted] miR?106b?5p promotes cell cycle progression of malignant melanoma by targeting PTEN.
    Oncol Rep. 2024;51:10.
    PubMed         Abstract available

    PLoS One

  14. SOARES PRO, Passos DCS, da Silva FM, da Silva-Giardini APB, et al
    In vitro antiproliferative and apoptotic effects of thiosemicarbazones based on (-)-camphene and R-(+)-limonene in human melanoma cells.
    PLoS One. 2023;18:e0295012.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.